Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Discovery and characterization of a novel CCND1/MRCK gene fusion in mantle cell lymphoma

Fig. 2

The CCND1/MRCK fusion is refractory to CCND1-targeted miRNA regulation and can be targeted for RNAi. a Quantitative real-time PCR (qRT-PCR) on mRNA extracted from different cell lines showing the expression levels of total CCND1 and the CCND1/MRCK chimera in each cell relative to levels in RPMI 1788. The * denotes expression levels of 374 and 347 for CCND1 and the chimeric mRNA, respectively. b Detection of CCND1/MRCK in MCL patient-derived DNA using PCR. c Dual luciferase reporter assay of HeLa cells after transfection with different miRNA mimics (48 h-post transfection) and plasmids (24 h-post transfection) containing the full-length 3′UTR of CCND1 (FL-CCND1), the Jeko-1 specific truncated CCND1 3′UTR (Tr-CCND1) and the CCND1/MRCK fusion 3′UTR. Shown are representative results of experiments performed in triplicate, with each miRNA compared to control using the t test. d A schematic showing the location of the sequences targeted by siRNAs with specific siRNAs targeting the protein-coding sequence of CCND1 (ORF) and the MRCK sequence from the CCND1/MRCK fusion (Chm). Western blot of cell lysates after nucleofection of Jeko-1 and Granta-519 with specific siRNAs targeting the protein-coding sequence of CCND1 (ORF) and the MRCK sequence from the CCND1/MRCK fusion (Chm)

Back to article page